Sometimes you win. Sometimes you lose. And sometimes it's just another PhIII canakinumab fail
At this stage of the game, Novartis CEO Vas Narasimhan may be wishing he’d never even heard of canakinumab.
After steering the drug straight to an FDA rejection as a heart drug, no cheap shot after testing it in 10,000 patients, the Novartis team picked up on an unusual cancer signal — and has now followed it over their third successive cliff to a decisive Phase III flop.
It’s safe to say the game was already all over except for the readout.
This article is for premium subscribers only
Upgrade to a premium subscription plan for unlimited access, and join our community of key biopharma players.